No­vo Nordisk notch­es big GLP-1 sales amid re­bound­ing sup­plies, but cau­tions on fu­ture 'pe­ri­od­ic con­straints'

With No­vo Nordisk’s obe­si­ty treat­ment We­govy ful­ly back in stock in De­cem­ber, sales are be­gin­ning to soar, the Dan­ish phar­ma re­port­ed dur­ing its an­nu­al earn­ings call on Wednes­day. To­tal scripts of the glucagon-like pep­tide 1 (GLP-1) We­govy topped 37,000 week­ly in mid-Jan­u­ary, a hock­ey stick uptick from end-of-year lev­els be­low 15,000 per week.

The new pre­scrip­tions come on top of the over­all mo­men­tum of No­vo obe­si­ty drug sales in 2022, al­though the then sup­ply-con­strained We­govy was on­ly part of that. Sib­ling obe­si­ty med Sax­en­da ac­count­ed for DKK 10.7 bil­lion ($1.58 bil­lion) of the to­tal DKK 16.9 bil­lion ($2.49 bil­lion), or about 63%, in No­vo Nordisk’s re­port­ed obe­si­ty seg­ment sales.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER